Table of Contents Table of Contents
Previous Page  49 / 62 Next Page
Information
Show Menu
Previous Page 49 / 62 Next Page
Page Background

Phase I study of Atezolizumab

ESMO 2016, 1425PD

•

ORR:

6% (RECIST), 18% (irRC)

1 … 44 45 46 47 48 49 50 51 52 53 54 55 … 62  FlippingBook